A Study of rSIFN-co in Subjects With Advanced Solid Tumors
NCT02387307
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
42
Enrollment
INDUSTRY
Sponsor class
Conditions
Carcinoma, Non-Small-Cell Lung
Carcinoma, Renal Cell
Melanoma
Carcinoma, Hepatocellular
Colon Cancer
Interventions
DRUG:
rSIFN-co
Sponsor
Sichuan Huiyang Life Science and Technology Corporation